People · Operator
Named in public records as an officer, director or promoter · active 2013–2016 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intezyne Technologies, Inc. | — | Pharmaceuticals | Series A | $9.3M | $14.9M | 2013 |
Kevin Sill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Sill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John McBride | 1 | 7 |
| Michael Cole | 1 | 3 |
| Michael Fountain | 1 | 2 |
| Daniel Devers | 1 | 2 |
| Hooshmand Sheshbaradaran | 1 | 2 |
| Habib Skaff | 1 | 1 |
| James Trotman | 1 | 1 |
| Micheal Cole | 1 | 1 |
| Carolyn Paradise | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.